{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:40:46Z","timestamp":1791265246567,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Secondary findings (SF) identified in massive parallel sequencing raise important clinical and healthcare related questions. To get an overview on current practices of European healthcare providers (HCP), we conducted a cross-sectional survey study among 39 stakeholders\u2014predominantly senior medical and laboratory geneticists\u2014from 15 European countries participating in the European Reference Network for Genetic Tumour Risk Syndromes (ERN GENTURIS). Respondents reported considerable heterogeneity in SF management and reporting, even within countries. While 31% of responding HCP return findings from all 81 genes on the American College of Medical Genetics and Genomics (ACMG) recommended SF list version 3.2, 41% restrict SF disclosure, often excluding genes associated with cardiological or metabolic disorders or with limited clinical actionability. A further 26% do not report ACMG-listed SF at all. Notably, 70% of HCP also assess additional cancer-predisposition genes beyond the ACMG list, using in-house gene lists or national guidelines. Most HCP restrict reporting to (likely) pathogenic variants (90%) and find SF in less than 5% of genetic analyses (59%). Consent procedures and patient information practices varied, with most HCP employing opt-in consent models and genetic counselling primarily delivered by medical geneticists and genetic counsellors. Major institutional challenges raised by participants, include lack of harmonised guidelines, concerns about patient anxiety, and insufficient resources for follow-up care. The findings of this study highlight the need for robust, evidence-based European guidelines to ensure clinically relevant and patient-centred SF management.<\/jats:p>","DOI":"10.1038\/s41431-026-02044-7","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T13:12:44Z","timestamp":1772543564000},"page":"1121-1129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reporting practices for secondary findings among ERN GENTURIS member institutions in 15 European countries"],"prefix":"10.1038","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0077-1385","authenticated-orcid":false,"given":"Kathrin","family":"Taxer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0732-7538","authenticated-orcid":false,"given":"Katharina","family":"Wimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Wadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5213-6237","authenticated-orcid":false,"given":"Simon","family":"Schnaiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8332-0672","authenticated-orcid":false,"given":"Sabine","family":"Rudnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0046-8274","authenticated-orcid":false,"given":"Johannes","family":"Zschocke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ERN GENTURIS Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Bajalica-Lagercrantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"van de Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Brems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"de Putter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Foretova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria K.","family":"Haanp\u00e4\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik J.","family":"Hes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiina","family":"Kahre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Klink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateja","family":"Krajc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Macchiaiolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Macek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjen","family":"Mensenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Percesepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Renieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6470-8612","authenticated-orcid":false,"given":"Tim","family":"Ripperger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Constanza Roa","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel R.","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Tesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Theis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"van Overeem Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildegunn H\u00f8berg","family":"Vetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2120-848X","authenticated-orcid":false,"given":"Gunda","family":"Schwaninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"2044_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10689-025-00457-9","volume":"24","author":"M Engels","year":"2025","unstructured":"Engels M, Urbanczyk K, H\u00f6lzenspies J, R\u00f6hl C, Geverink N, Hoogerbrugge N. The European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS): benefits for patients, families, and health care providers. Fam Cancer. 2025;24:33. https:\/\/doi.org\/10.1007\/s10689-025-00457-9.","journal-title":"Fam Cancer"},{"key":"2044_CR2","unstructured":"European Commission Public Health. Rare diseases and European Reference Networks. (Website visited June 2025)."},{"key":"2044_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12910-020-0452-0","volume":"21","author":"M Saelaert","year":"2020","unstructured":"Saelaert M, Mertes H, Moerenhout T, De Baere E, Devisch I. Ethical values supporting the disclosure of incidental and secondary findings in clinical genomic testing: a qualitative study. BMC Med Ethics. 2020;21:9. https:\/\/doi.org\/10.1186\/s12910-020-0452-0.","journal-title":"BMC Med Ethics"},{"key":"2044_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41431-020-00758-w","volume":"29","author":"G de Wert","year":"2021","unstructured":"de Wert G, Dondorp W, Clarke A, Dequeker EMC, Cordier C, Deans Z, et al. Opportunistic genomic screening. Recommendations of the European Society of Human Genetics. Eur J Hum Genet. 2021;29:365\u201377. https:\/\/doi.org\/10.1038\/s41431-020-00758-w.","journal-title":"Eur J Hum Genet"},{"key":"2044_CR5","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1016\/j.ajhg.2024.08.012","volume":"111","author":"S Majeed","year":"2024","unstructured":"Majeed S, Johnston C, Saeedi S, Mighton C, Rokoszak V, Abbasi I, et al. International policies guiding the selection, analysis, and clinical management of secondary findings from genomic sequencing: a systematic review. Am J Hum Genet. 2024;111:2079\u201393. https:\/\/doi.org\/10.1016\/j.ajhg.2024.08.012.","journal-title":"Am J Hum Genet"},{"key":"2044_CR6","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/s41436-021-01171-4","volume":"23","author":"DT Miller","year":"2021","unstructured":"Miller DT, Lee K, Gordon AS, Amendola LM, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23:1391\u20138. https:\/\/doi.org\/10.1038\/s41436-021-01171-4.","journal-title":"Genet Med"},{"key":"2044_CR7","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1038\/s41431-018-0224-1","volume":"26","author":"P Pujol","year":"2018","unstructured":"Pujol P, Vande Perre P, Faivre L, Sanlaville D, Corsini C, Baertschi B, et al. Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations. Eur J Hum Genet. 2018;26:1732\u201342. https:\/\/doi.org\/10.1038\/s41431-018-0224-1.","journal-title":"Eur J Hum Genet"},{"key":"2044_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ajhg.2020.05.002","volume":"107","author":"AE Katz","year":"2020","unstructured":"Katz AE, Nussbaum RL, Solomon BD, Rehm HL, Williams MS, Biesecker LG. Management of secondary genomic findings. Am J Hum Genet. 2020;107:3\u201314. https:\/\/doi.org\/10.1016\/j.ajhg.2020.05.002.","journal-title":"Am J Hum Genet"},{"key":"2044_CR9","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/s41431-019-0438-x","volume":"27","author":"B Isidor","year":"2019","unstructured":"Isidor B, Julia S, Saugier-Veber P, Weil-Dubuc PL, B\u00e9zieau S, Bieth E, et al. Searching for secondary findings: considering actionability and preserving the right not to know. Eur J Hum Genet. 2019;27:1481\u20134.\u00a0https:\/\/doi.org\/10.1038\/s41431-019-0438-x.","journal-title":"Eur J Hum Genet"},{"key":"2044_CR10","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/s41436-018-0308-x","volume":"21","author":"MR Hart","year":"2019","unstructured":"Hart MR, Biesecker BB, Blout CL, Christensen KD, Amendola LM, Bergstrom KL, et al. Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite study. Genet Med. 2019;21:1100\u201310. https:\/\/doi.org\/10.1038\/s41436-018-0308-x.","journal-title":"Genet Med"},{"key":"2044_CR11","doi-asserted-by":"publisher","first-page":"e0135193","DOI":"10.1371\/journal.pone.0135193","volume":"10","author":"E Olfson","year":"2015","unstructured":"Olfson E, Cottrell CE, Davidson NO, Gurnett CA, Heusel JW, Stitziel NO, et al. Identification of medically actionable secondary findings in the 1000 genomes. PLoS One. 2015;10:e0135193. https:\/\/doi.org\/10.1371\/journal.pone.0135193.","journal-title":"PLoS One"},{"key":"2044_CR12","doi-asserted-by":"publisher","unstructured":"Deutsche Gesellschaft f\u00fcr Humangenetik e.V. (GfH). 24102023 Stellungnahme der Deutschen Gesellschaft f\u00fcr Humangenetik zu Zusatz- und Zufallsbefunden in der genetischen Diagnostik. 2023;35:313-21. https:\/\/doi.org\/10.1515\/medgen-2023-2060.","DOI":"10.1515\/medgen-2023-2060"},{"key":"2044_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.2180","volume":"11","author":"M Brunfeldt","year":"2023","unstructured":"Brunfeldt M, Kaare M, Saarinen I, Koskenvuo J, K\u00e4\u00e4ri\u00e4inen H. Opt-in for secondary findings as part of diagnostic whole-exome sequencing: Real-life experience from an international diagnostic laboratory. Mol Genet Genom Med. 2023;11:e2180. https:\/\/doi.org\/10.1002\/mgg3.2180.","journal-title":"Mol Genet Genom Med"},{"key":"2044_CR14","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1038\/s41436-021-01295-7","volume":"23","author":"JC Sapp","year":"2021","unstructured":"Sapp JC, Facio FM, Cooper D, Lewis KL, Modlin E, van der Wees P, et al. A systematic literature review of disclosure practices and reported outcomes for medically actionable genomic secondary findings. Genet Med. 2021;23:2260\u20139. https:\/\/doi.org\/10.1038\/s41436-021-01295-7.","journal-title":"Genet Med"},{"key":"2044_CR15","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.3390\/ijms26083509","volume":"26","author":"M Melo","year":"2025","unstructured":"Melo M, Ribeiro M, Silva PF, Valente S, Alves F, Ven\u00e2ncio M, et al. Medically Actionable Secondary Findings from Whole-Exome Sequencing (WES) Data in a Sample of 3972 Individuals. Int J Mol Sci. 2025;26:3509. https:\/\/doi.org\/10.3390\/ijms26083509.","journal-title":"Int J Mol Sci"},{"key":"2044_CR16","doi-asserted-by":"publisher","first-page":"364ra151","DOI":"10.1126\/scitranslmed.aag2367","volume":"8","author":"P Natarajan","year":"2016","unstructured":"Natarajan P, Gold NB, Bick AG, McLaughlin H, Kraft P, Rehm HL, et al. Aggregate penetrance of genomic variants for actionable disorders in European and African Americans. Sci Transl Med. 2016;8:364ra151. https:\/\/doi.org\/10.1126\/scitranslmed.aag2367.","journal-title":"Sci Transl Med"},{"key":"2044_CR17","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00439-025-02746-w","volume":"144","author":"E Avsec","year":"2025","unstructured":"Avsec E, Blatnik A, Krajc M. Secondary findings in hereditary cancer genes after germline genetic testing - systematic review of literature. Hum Genet. 2025;144:595\u2013604. https:\/\/doi.org\/10.1007\/s00439-025-02746-w.","journal-title":"Hum Genet"},{"key":"2044_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2023.100866","volume":"25","author":"DT Miller","year":"2023","unstructured":"Miller DT, Lee K, Abul-Husn NS, Amendola LM, Brothers K, Chung WK, et al. ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2023;25:100866. https:\/\/doi.org\/10.1016\/j.gim.2023.100866.","journal-title":"Genet Med"},{"key":"2044_CR19","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/humu.23259","volume":"38","author":"DF Vears","year":"2017","unstructured":"Vears DF, S\u00e9n\u00e9cal K, Borry P. Reporting practices for unsolicited and secondary findings from next-generation sequencing technologies: Perspectives of laboratory personnel. Hum Mutat. 2017;38:905\u201311. https:\/\/doi.org\/10.1002\/humu.23259.","journal-title":"Hum Mutat"},{"key":"2044_CR20","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1038\/ejhg.2015.111","volume":"23","author":"JY Hehir-Kwa","year":"2015","unstructured":"Hehir-Kwa JY, Claustres M, Hastings RJ, van Ravenswaaij-Arts C, Christenhusz G, Genuardi M, et al. Towards a European consensus for reporting incidental findings during clinical NGS testing. Eur J Hum Genet. 2015;23:1601\u20136. https:\/\/doi.org\/10.1038\/ejhg.2015.111.","journal-title":"Eur J Hum Genet"},{"key":"2044_CR21","doi-asserted-by":"publisher","unstructured":"ACMG SF v3.3 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG). Genetics Med. 2025;27:101454. https:\/\/doi.org\/10.1016\/j.gim.2025.101454","DOI":"10.1016\/j.gim.2025.101454"},{"key":"2044_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2023.101051","volume":"26","author":"J Nolan","year":"2024","unstructured":"Nolan J, Buchanan J, Taylor J, Almeida J, Bedenham T, Blair E, et al. Secondary (additional) findings from the 100,000 Genomes Project: Disease manifestation, health care outcomes, and costs of disclosure. Genet Med. 2024;26:101051. https:\/\/doi.org\/10.1016\/j.gim.2023.101051.","journal-title":"Genet Med"},{"key":"2044_CR23","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1136\/jmedgenet-2015-103144","volume":"52","author":"K Boycott","year":"2015","unstructured":"Boycott K, Hartley T, Adam S, Bernier F, Chong K, Fernandez BA, et al. The clinical application of genome-wide sequencing for monogenic diseases in Canada: Position Statement of the Canadian College of Medical Geneticists. J Med Genet. 2015;52:431\u20137. https:\/\/doi.org\/10.1136\/jmedgenet-2015-103144.","journal-title":"J Med Genet"},{"key":"2044_CR24","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/ejhg.2013.46","volume":"21","author":"CG van El","year":"2013","unstructured":"van El CG, Cornel MC, Borry P, Hastings RJ, Fellmann F, Hodgson SV, et al. Whole-genome sequencing in health care. Eur J Hum Genet. 2013;21:580\u20134. https:\/\/doi.org\/10.1038\/ejhg.2013.46.","journal-title":"Eur J Hum Genet"},{"key":"2044_CR25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/gim.2016.109","volume":"19","author":"MP Mackley","year":"2017","unstructured":"Mackley MP, Fletcher B, Parker M, Watkins H, Ormondroyd E. Stakeholder views on secondary findings in whole-genome and whole-exome sequencing: a systematic review of quantitative and qualitative studies. Genet Med. 2017;19:283\u201393. https:\/\/doi.org\/10.1038\/gim.2016.109.","journal-title":"Genet Med"},{"key":"2044_CR26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324. https:\/\/doi.org\/10.1038\/gim.2015.30.","journal-title":"Genet Med"},{"key":"2044_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-021-01016-8","volume":"14","author":"JE Cl\u00e9ophat","year":"2021","unstructured":"Cl\u00e9ophat JE, Dorval M, El Haffaf Z, Chiquette J, Collins S, Malo B, et al. Whether, when, how, and how much? General public\u2019s and cancer patients\u2019 views about the disclosure of genomic secondary findings. BMC Med Genomics. 2021;14:167. https:\/\/doi.org\/10.1186\/s12920-021-01016-8.","journal-title":"BMC Med Genomics"},{"key":"2044_CR28","doi-asserted-by":"publisher","unstructured":"Rego S, Grove ME, Cho MK, Ormond KE. Informed consent in the genomics era. Cold Spring Harb Perspect Med. 2020;10. https:\/\/doi.org\/10.1101\/cshperspect.a036582","DOI":"10.1101\/cshperspect.a036582"},{"key":"2044_CR29","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s41431-021-00828-7","volume":"29","author":"A Woudstra","year":"2021","unstructured":"Woudstra A, Dondorp W, de Wert G. Stakeholder views on opportunistic genomic screening in the Netherlands: a qualitative study. Eur J Hum Genet. 2021;29:949\u201356. https:\/\/doi.org\/10.1038\/s41431-021-00828-7.","journal-title":"Eur J Hum Genet"},{"key":"2044_CR30","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s10897-017-0172-x","volume":"27","author":"J Wynn","year":"2018","unstructured":"Wynn J, Martinez J, Bulafka J, Duong J, Zhang Y, Chiuzan C, et al. Impact of Receiving Secondary Results from Genomic Research: A 12-Month Longitudinal Study. J Genet Couns. 2018;27:709\u201322. https:\/\/doi.org\/10.1007\/s10897-017-0172-x.","journal-title":"J Genet Couns"},{"key":"2044_CR31","doi-asserted-by":"publisher","first-page":"103711","DOI":"10.1016\/j.ejmg.2019.103711","volume":"62","author":"F Houdayer","year":"2019","unstructured":"Houdayer F, Putois O, Babonneau ML, Chaumet H, Joly L, Juif C, et al. Secondary findings from next generation sequencing: Psychological and ethical issues. Family and patient perspectives. Eur J Med Genet. 2019;62:103711. https:\/\/doi.org\/10.1016\/j.ejmg.2019.103711.","journal-title":"Eur J Med Genet"},{"key":"2044_CR32","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/jgc4.1386","volume":"30","author":"MLB Schwartz","year":"2021","unstructured":"Schwartz MLB, Buchanan AH, Hallquist MLG, Haggerty CM, Sturm AC. Genetic counseling for patients with positive genomic screening results: Considerations for when the genetic test comes first. J Genet Couns. 2021;30:634\u201344. https:\/\/doi.org\/10.1002\/jgc4.1386.","journal-title":"J Genet Couns"}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02044-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02044-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02044-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:02:34Z","timestamp":1785445354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02044-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2044"],"URL":"https:\/\/doi.org\/10.1038\/s41431-026-02044-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7317728\/v1","asserted-by":"object"}]},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KW: Honorarium for lecture regarding breast cancer from Seagen, Thomas v. O. Hansen has received lecture fees from AstraZeneca\/MSD; The other authors did not declare a competing of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All data presented were retrieved from a voluntary survey. Participants were made aware that answers would be used for publication on the first page of the survey. The option for fully anonymised participation was given to all participants. The research did not qualify for submission to an IRB or research ethics committee at the Medical University of Innsbruck, as only experts professionals received the survey.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}